Therapy Detail

Therapy Name BC21
Therapy Description

BC21 inhibits the interaction of CTNNB1 with TCF7L2 to block Wnt signaling, which can prevent cell proliferation and induce apoptosis (PMID: 22224445).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
BC21 CTNNB1 Inhibitor 26 BC21 inhibits the interaction of CTNNB1 with TCF7L2 to block Wnt signaling, which can prevent cell proliferation and induce apoptosis (PMID: 22224445).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CTNNB1 mutant colorectal cancer sensitive BC21 Preclinical Actionable In a preclinical study, BC21 inhibited growth and viability of a colorectal cancer cell line with a CTNNB1 mutation and increased beta-catenin expression in culture (PMID: 22224445). 22224445
Clinical Trial Phase Therapies Title Recruitment Status